Tardive dyskinesia in 2 patients treated with ziprasidone.
|Title||Tardive dyskinesia in 2 patients treated with ziprasidone.|
|Publication Type||Journal Article|
|Year of Publication||2004|
|Authors||Ananth, J, Burgoyne KS, Niz D, Smith M|
|Journal||Journal of psychiatry & neuroscience : JPN|
|Date Published||2004 Nov|
|Keywords||Adult, Antipsychotic Agents, Delusions, Dose-Response Relationship, Drug, Drug Administration Schedule, Dyskinesia, Drug-Induced, Follow-Up Studies, Hallucinations, Humans, Long-Term Care, Male, Neurologic Examination, Piperazines, Psychiatric Status Rating Scales, Recurrence, Schizophrenia, Thiazoles|
Ziprasidone is an atypical antipsychotic drug that is believed to have a low propensity for inducing extrapyramidal symptoms, including tardive dyskinesia (TD). Two of our patients developed TD after 23 months and 34 months of ziprasidone monotherapy, respectively. One of the patients had had earlier exposure to typical antipsychotic drugs, but no other predisposing factors for TD were noted. Therefore, patients on long-term therapy with atypical antipsychotic drugs should be screened periodically for TD.
|Alternate Journal||J Psychiatry Neurosci|